메뉴 건너뛰기




Volumn 60, Issue 1, 2014, Pages 222-232

Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 14; FIBROBLAST GROWTH FACTOR 18; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR 5; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 4; KERATINOCYTE GROWTH FACTOR;

EID: 84891819848     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.211490     Document Type: Article
Times cited : (40)

References (40)
  • 2
    • 79954493924 scopus 로고    scopus 로고
    • Committee opinion no 477 the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer
    • American College of Obstetricians and Gynecologists Committee on Gynecologic Practice.
    • American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee opinion no. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117: 742-6.
    • (2011) Obstet Gynecol , vol.117 , pp. 742-746
  • 3
    • 84863078516 scopus 로고    scopus 로고
    • Vignette-based study of ovarian cancer screening: Do U.S physicians report adhering to evidence-based recommendations?
    • Baldwin LM, Trivers KF, Matthews B, Andrilla CH, Miller JW, Berry DL, et al. Vignette-based study of ovarian cancer screening: Do U.S. physicians report adhering to evidence-based recommendations? Ann Intern Med 2012;156: 182-94.
    • (2012) Ann Intern Med , vol.156 , pp. 182-194
    • Baldwin, L.M.1    Trivers, K.F.2    Matthews, B.3    Andrilla, C.H.4    Miller, J.W.5    Berry, D.L.6
  • 5
    • 79958036419 scopus 로고    scopus 로고
    • Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
    • for the PLCO Project Team.
    • Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al., for the PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305: 2295-303.
    • (2011) JAMA , vol.305 , pp. 2295-2303
    • Buys, S.S.1    Partridge, E.2    Black, A.3    Johnson, C.C.4    Lamerato, L.5    Isaacs, C.6
  • 6
    • 77957571905 scopus 로고    scopus 로고
    • A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24
    • Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010;42: 874-9.
    • (2010) Nat Genet , vol.42 , pp. 874-879
    • Goode, E.L.1    Chenevix-Trench, G.2    Song, H.3    Ramus, S.J.4    Notaridou, M.5    Lawrenson, K.6
  • 7
    • 69349102630 scopus 로고    scopus 로고
    • A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2
    • Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry- Maharaj A, Wozniak E, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009; 41: 996-1000.
    • (2009) Nat Genet , vol.41 , pp. 996-1000
    • Song, H.1    Ramus, S.J.2    Tyrer, J.3    Bolton, K.L.4    Gentry- Maharaj, A.5    Wozniak, E.6
  • 8
    • 77957584092 scopus 로고    scopus 로고
    • Common variants at 19p13 are associated with susceptibility to ovarian cancer
    • Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010;42: 880-4.
    • (2010) Nat Genet , vol.42 , pp. 880-884
    • Bolton, K.L.1    Tyrer, J.2    Song, H.3    Ramus, S.J.4    Notaridou, M.5    Jones, C.6
  • 9
    • 84875707717 scopus 로고    scopus 로고
    • GWAS metaanalysis and replication identifies three new susceptibility loci for ovarian cancer
    • 70e1-2
    • Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, et al. GWAS metaanalysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013;45:362-70, 70e1-2.
    • (2013) Nat Genet , vol.45 , pp. 362-370
    • Pharoah, P.D.1    Tsai, Y.Y.2    Ramus, S.J.3    Phelan, C.M.4    Goode, E.L.5    Lawrenson, K.6
  • 10
    • 84858853451 scopus 로고    scopus 로고
    • Role of common genetic variants in ovarian cancer susceptibility and outcome: Progress to date from the Ovarian Cancer Association Consortium (OCAC)
    • Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J Intern Med 2012;271: 366-78.
    • (2012) J Intern Med , vol.271 , pp. 366-378
    • Bolton, K.L.1    Ganda, C.2    Berchuck, A.3    Pharaoh, P.D.4    Gayther, S.A.5
  • 11
    • 34748848707 scopus 로고    scopus 로고
    • Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients
    • DOI 10.1016/j.ygyno.2007.07.024, PII S0090825807004957
    • Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, et al. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 2007;107:S223-9. (Pubitemid 47487477)
    • (2007) Gynecologic Oncology , vol.107 , Issue.1 SUPPL.
    • Saldivar, J.S.1    Lu, K.H.2    Liang, D.3    Gu, J.4    Huang, M.5    Vlastos, A.-T.6    Follen, M.7    Wu, X.8
  • 12
    • 80053591338 scopus 로고    scopus 로고
    • Genetic variants in TGF- pathway are associated with ovarian cancer risk
    • Yin J, Lu K, Lin J, Wu L, Hildebrandt MA, Chang DW, et al. Genetic variants in TGF- pathway are associated with ovarian cancer risk. PLoS One 2011;6:e25559.
    • (2011) PLoS One , vol.6
    • Yin, J.1    Lu, K.2    Lin, J.3    Wu, L.4    Hildebrandt, M.A.5    Chang, D.W.6
  • 13
    • 78649977193 scopus 로고    scopus 로고
    • Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response
    • Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, et al. Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res 2010;70: 9765-76.
    • (2010) Cancer Res , vol.70 , pp. 9765-9776
    • Liang, D.1    Meyer, L.2    Chang, D.W.3    Lin, J.4    Pu, X.5    Ye, Y.6
  • 14
    • 84859415553 scopus 로고    scopus 로고
    • Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer
    • Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012;18: 1855-62.
    • (2012) Clin Cancer Res , vol.18 , pp. 1855-1862
    • Brooks, A.N.1    Kilgour, E.2    Smith, P.D.3
  • 16
    • 75149170979 scopus 로고    scopus 로고
    • Fibroblast growth factor signalling: From development to cancer
    • Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10: 116-29.
    • (2010) Nat Rev Cancer , vol.10 , pp. 116-129
    • Turner, N.1    Grose, R.2
  • 17
    • 79959713140 scopus 로고    scopus 로고
    • Fibroblast growth factors and their receptors in cancer
    • Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011;437: 199-213.
    • (2011) Biochem J , vol.437 , pp. 199-213
    • Wesche, J.1    Haglund, K.2    Haugsten, E.M.3
  • 19
    • 84874030601 scopus 로고    scopus 로고
    • Identification of FGFR4 as a potential therapeutic target for advancedstage, high-grade serous ovarian cancer
    • Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, et al. Identification of FGFR4 as a potential therapeutic target for advancedstage, high-grade serous ovarian cancer. Clin Cancer Res 2013;19: 809-20.
    • (2013) Clin Cancer Res , vol.19 , pp. 809-820
    • Zaid, T.M.1    Yeung, T.L.2    Thompson, M.S.3    Leung, C.S.4    Harding, T.5    Co, N.N.6
  • 21
    • 33644855779 scopus 로고    scopus 로고
    • From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer
    • DOI 10.1002/ijc.21521
    • Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer 2006;118: 1750-8. (Pubitemid 43376439)
    • (2006) International Journal of Cancer , vol.118 , Issue.7 , pp. 1750-1758
    • Le Page, C.1    Ouellet, V.2    Madore, J.3    Hudson, T.J.4    Tonin, P.N.5    Provencher, D.M.6    Mes-Masson, A.-M.7
  • 22
    • 34250200790 scopus 로고    scopus 로고
    • Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas
    • DOI 10.1200/JCO.2006.09.0795
    • Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, et al. Whole genome oligonucleotidebased array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. Clin Oncol 2007;25: 2281-7. (Pubitemid 46954656)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.16 , pp. 2281-2287
    • Birrer, M.J.1    Johnson, M.E.2    Hao, K.3    Wong, K.-K.4    Park, D.-C.5    Bell, A.6    Welch, W.R.7    Berkowitz, R.S.8    Mok, S.C.9
  • 23
    • 84867395354 scopus 로고    scopus 로고
    • Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer
    • Smith G, Ng MT, Shepherd L, Herrington CS, Gourley C, Ferguson MJ, Wolf CR. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. Br J Cancer 2012;107: 1327-36.
    • (2012) Br J Cancer , vol.107 , pp. 1327-1336
    • Smith, G.1    Ng, M.T.2    Shepherd, L.3    Herrington, C.S.4    Gourley, C.5    Ferguson, M.J.6    Wolf, C.R.7
  • 24
    • 76749136307 scopus 로고    scopus 로고
    • Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype
    • Murphy T, Darby S, Mathers ME, Gnanapragasam VJ. Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol 2010;220: 452-60.
    • (2010) J Pathol , vol.220 , pp. 452-460
    • Murphy, T.1    Darby, S.2    Mathers, M.E.3    Gnanapragasam, V.J.4
  • 26
    • 79952818552 scopus 로고    scopus 로고
    • Overview of anti-angiogenic agents in development for ovarian cancer
    • Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011;121: 230-8.
    • (2011) Gynecol Oncol , vol.121 , pp. 230-238
    • Burger, R.A.1
  • 27
    • 80053493427 scopus 로고    scopus 로고
    • Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis
    • Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011;17: 6130-9.
    • (2011) Clin Cancer Res , vol.17 , pp. 6130-6139
    • Lieu, C.1    Heymach, J.2    Overman, M.3    Tran, H.4    Kopetz, S.5
  • 28
    • 67249140681 scopus 로고    scopus 로고
    • Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: Results from the Ovarian Cancer Association Consortium
    • Johnatty SE, Beesley J, Chen X, Spurdle AB, Defazio A, Webb PM, et al. Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the Ovarian Cancer Association Consortium. Twin Res Hum Genet 2009;12: 269-75.
    • (2009) Twin Res Hum Genet , vol.12 , pp. 269-275
    • Johnatty, S.E.1    Beesley, J.2    Chen, X.3    Spurdle, A.B.4    Defazio, A.5    Webb, P.M.6
  • 31
    • 77957232748 scopus 로고    scopus 로고
    • Genevar: A database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies
    • Yang TP, Beazley C, Montgomery SB, Dimas AS, Gutierrez-Arcelus M, Stranger BE, et al. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 2010;26: 2474-6.
    • (2010) Bioinformatics , vol.26 , pp. 2474-2476
    • Yang, T.P.1    Beazley, C.2    Montgomery, S.B.3    Dimas, A.S.4    Gutierrez-Arcelus, M.5    Stranger, B.E.6
  • 32
    • 36648999834 scopus 로고    scopus 로고
    • FGF signaling in prostate tumorigenesis-new insights into epithelial-stromal interactions
    • DOI 10.1016/j.ccr.2007.11.021, PII S1535610807003418
    • Abate-Shen C, Shen MM. FGF signaling in prostate tumorigenesis - new insights into epithelialstromal interactions. Cancer Cell 2007;12: 495-7. (Pubitemid 350199077)
    • (2007) Cancer Cell , vol.12 , Issue.6 , pp. 495-497
    • Abate-Shen, C.1    Shen, M.M.2
  • 33
    • 36649036989 scopus 로고    scopus 로고
    • Enhanced Paracrine FGF10 Expression Promotes Formation of Multifocal Prostate Adenocarcinoma and an Increase in Epithelial Androgen Receptor
    • DOI 10.1016/j.ccr.2007.11.002, PII S1535610807003339
    • Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, Witte ON. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 2007;12: 572-85. (Pubitemid 350199069)
    • (2007) Cancer Cell , vol.12 , Issue.6 , pp. 572-585
    • Memarzadeh, S.1    Xin, L.2    Mulholland, D.J.3    Mansukhani, A.4    Wu, H.5    Teitell, M.A.6    Witte, O.N.7
  • 34
    • 61649100307 scopus 로고    scopus 로고
    • The FGF family: Biology, pathophysiology and therapy
    • Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8: 235-53.
    • (2009) Nat Rev Drug Discov , vol.8 , pp. 235-253
    • Beenken, A.1    Mohammadi, M.2
  • 35
    • 0035855624 scopus 로고    scopus 로고
    • Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer
    • DOI 10.1038/sj.onc.1204755
    • Steele IA, Edmondson RJ, Bulmer JN, Bolger BS, Leung HY, Davies BR. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene 2001;20: 5878-87. (Pubitemid 32937957)
    • (2001) Oncogene , vol.20 , Issue.41 , pp. 5878-5887
    • Steele, I.A.1    Edmondson, R.J.2    Bulmer, J.N.3    Bolger, B.S.4    Leung, H.Y.5    Davies, B.R.6
  • 36
    • 77957116888 scopus 로고    scopus 로고
    • Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer
    • Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C, et al. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther 2010;10: 495-504.
    • (2010) Cancer Biol Ther , vol.10 , pp. 495-504
    • Cole, C.1    Lau, S.2    Backen, A.3    Clamp, A.4    Rushton, G.5    Dive, C.6
  • 38
    • 30944460953 scopus 로고    scopus 로고
    • Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines
    • DOI 10.1080/08977190500361697, PII X1174636870X4201
    • Steele IA, Edmondson RJ, Leung HY, Davies BR. Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines. Growth Factors 2006;24: 45-53. (Pubitemid 43108775)
    • (2006) Growth Factors , vol.24 , Issue.1 , pp. 45-53
    • Steele, I.A.1    Edmondson, R.J.2    Leung, H.Y.3    Davies, B.R.4
  • 39
    • 84872294755 scopus 로고    scopus 로고
    • Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells
    • Byron SA, Loch DC, Pollock PM. Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. Int J Gynecol Cancer 2012;22: 1517-26.
    • (2012) Int J Gynecol Cancer , vol.22 , pp. 1517-1526
    • Byron, S.A.1    Loch, D.C.2    Pollock, P.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.